pyridin-3-ylmethyl 1H-imidazole-1-carboxylate | 212632-27-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: pyridin-3-ylmethyl 1H-imidazole-1-carboxylate
• 英文别名: pyrid-3-ylmethyl carbonylimidazolide；(pyridin-3-yl)methyl 1H-imidazole-1-carboxylate；3-pyridylmethyl 1H-imidazole-1-carboxylate；1H-Imidazole-1-carboxylic acid, 3-pyridinylmethyl ester；pyridin-3-ylmethyl imidazole-1-carboxylate
• CAS: 212632-27-4
• 化学式: C₁₀H₉N₃O₂
• 分子量: 203.2
• InChiKey: QMRRRKQPTJYPDJ-UHFFFAOYSA-N

物化性质

• 沸点：
  396.9±44.0 °C(Predicted)
• 密度：
  1.26±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  57
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  pyridin-3-ylmethyl 1H-imidazole-1-carboxylate 在 草酰氯 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三乙胺 、 N,N-二甲基甲酰胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 25.0h， 生成 恩替诺特
  参考文献：
  名称：

  Synthesis and Histone Deacetylase Inhibitory Activity of New Benzamide Derivatives

  摘要：

  Newly synthesized benzamide derivatives were evaluated for their inhibitory activity against histone deacetylase. The structure of these derivatives was unrelated to the known inhibitors, and IC50 values of the active compounds were in the range of 2-50 mu M. Structure-activity relationship on the benzanilide moiety showed that the 2'-substituent, an amino or hydroxy group, was indispensable for inhibitory activity. Although the electronic influence of the substituent in the anilide moiety showed only a small effect on inhibitory activity, the steric factor in the anilide moiety, especially at positions 3'and 4', played an important role in interaction with the enzyme. Among these benzamide derivatives, MS-275 (1), which showed significant antitumor activity in vivo, has been selected for further investigation.

  DOI：

  10.1021/jm980565u
• 作为产物：
  描述：

  3-吡啶甲醇 、 N,N'-羰基二咪唑 在 水 、 二氯甲烷 、 Sodium sulfate-III 、 silica gel 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 以gave (pyridin-3-yl)methyl 1H-imidazole-1-carboxylate (3.1 g, 84%)的产率得到pyridin-3-ylmethyl 1H-imidazole-1-carboxylate
  参考文献：
  名称：

  Quinazolines useful as modulators of ion channels

  摘要：

  本发明涉及作为电压门控钠通道抑制剂有用的化合物。本发明还提供了包括本发明化合物的药学上可接受的组合物，以及使用这些组合物治疗各种疾病的方法。

  公开号：

  US20060173018A1

文献信息

• Spirocyclic compounds
  申请人：Berk C. Scott

  公开号：US20070117824A1

  公开（公告）日：2007-05-24

  The present invention relates to a novel class of substituted spirocyclic compounds. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the compounds of the instant invention and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of these compounds in vivo.

  本发明涉及一类新型的取代螺环化合物。这些化合物可以抑制组蛋白去乙酰化酶，并适用于在选择性诱导终末分化、阻止肿瘤细胞生长和/或凋亡的过程中使用，从而抑制这些细胞的增殖。因此，本发明的化合物在治疗具有肿瘤特征的患者方面是有用的，这些肿瘤具有肿瘤细胞的增殖。本发明的化合物还可能在预防和治疗TRX介导的疾病方面有用，例如自身免疫、过敏和炎症性疾病，以及预防和/或治疗中枢神经系统（CNS）疾病，如神经退行性疾病。本发明还提供了包括本发明化合物的药物组合物和这些药物组合物的安全用药方案，这些方案易于遵循，并在体内产生这些化合物的治疗有效量。
• [EN] PEPTIDIC THROMBIN INHIBITOR COMPOUND<br/>[FR] COMPOSE PEPTIDIQUE INHIBITEUR DE LA THROMBINE
  申请人：LG LIFE SCIENCES LTD

  公开号：WO2004002985A1

  公开（公告）日：2004-01-08

  The present invention relates to a novel thrombin inhibitor compound which has a good inhibitory effect against thrombosis and can be orally administered, a process for preparing the same, and to a composition for the therapeutic and/or prophylactic treatment of various diseases associated with thrombin inhibition mechanism, which comprises the same as an active ingredient.

  本发明涉及一种新颖的凝血酶抑制剂化合物，它对血栓具有很好的抑制作用，可以口服给药，其制备方法，以及包含该化合物作为活性成分的用于治疗和/或预防与凝血酶抑制机制相关联的各种疾病的组合物。
• [EN] QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS<br/>[FR] QUINAZOLINES UTILES EN TANT QUE MODULATEURS DE CANAUX IONIQUES
  申请人：VERTEX PHARMA

  公开号：WO2006028904A1

  公开（公告）日：2006-03-16

  The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

  本发明涉及作为电压门控钠通道抑制剂的化合物。该发明还提供了包含本发明化合物的药用可接受组合物，以及使用这些组合物治疗各种疾病的方法。
• Indane amides
  申请人：Wang Yamin

  公开号：US20090247590A1

  公开（公告）日：2009-10-01

  The invention relates to novel compounds and processes for their preparation and their use for preparing medicaments for the treatment of disorders, especially hyper-proliferative disorders.

  该发明涉及新化合物及其制备方法，以及用于制备治疗疾病的药物，特别是治疗过度增殖性疾病的药物。
• SPIROCYCLIC COMPOUNDS
  申请人：Mampreian Dawn M.

  公开号：US20110098268A1

  公开（公告）日：2011-04-28

  The present invention relates to a novel class of substituted spirocyclic compounds. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the compounds of the instant invention and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of these compounds in vivo.

  本发明涉及一种新型的取代螺环化合物。这些化合物可以抑制组蛋白去乙酰化酶，并适用于在选择性诱导末端分化、阻止肿瘤细胞的增殖和/或凋亡，从而抑制这些细胞的增殖中使用。因此，本发明的化合物可用于治疗具有肿瘤细胞增殖特征的患者。本发明的化合物还可用于预防和治疗TRX介导的疾病，例如自身免疫性、过敏性和炎症性疾病，并用于预防和/或治疗中枢神经系统（CNS）疾病，例如神经退行性疾病。本发明还提供了包含本发明化合物的药物组合物和这些药物组合物的安全剂量方案，这些方案易于遵循，并在体内产生治疗有效量的这些化合物。